Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Recent And Upcoming FDA Advisory Committee Meetings

Executive Summary

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

You may also be interested in...



Antibacterial Drugs: FDA Panel To Explore Approval Path For Single-Species Agents

US agency’s advisory committee will weigh the pros and cons of five possible development and regulatory pathways, with a specific focus on animal models.

RoxyBond Gets US Advisory Panel OK For Abuse-Deterrent Claim Despite Excipient Concerns

Members unanimously endorse product and mostly supported abuse-deterrent language; several panelists suggest warning about possible harmful effects of excipients by abusing product intravenously.

Funding Doubles Women’s Health Firm Perelel’s Support, Boosts Odyssey Elixir Energy Visibility

Perelel doubles its support and makes $10m pledge to women’s health research groups; Odyssey Wellness starts boosting brand visibility for energy drinks with lion’s mane and cordyceps mushrooms.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS120446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel